Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds to hydroxyapatite in bone and inhibits crystal growth and dissolution. At sufficient exposure it is taken up by osteoclasts and suppresses osteoclastic bone resorption; unlike nitrogen-containing bisphosphonates it does not inhibit farnesyl pyrophosphate synthase.
Indications / reported uses
Treatment of Paget’s disease of bone
Prevention and treatment of heterotopic ossification in selected settings
Treatment of hypercalcaemia associated with malignancy in historical or product-specific settings; check current availability and local label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Etidronate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Etidronate Permitted Daily Exposure (PDE) report (the Etidronate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Etidronate Occupational Exposure Limit (OEL) report (the Etidronate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.